SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Biological qualification of blood units
7 references·1 citing·29 second hop
Biological qualification of blood units (2004)Biological qualification of blood unitsTrends in residual risk of transfusion‐transmitted viral infections in France between 1992 and 2000 (2002)Trends in residual risk of tr…Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy (2002)Residual risk of transfusion‐…Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT (2002)Mathematic modeling of the ri…International application of the Incidence Rate/Window Period model (2002)International application of …Estimated risk of transfusion‐transmitted viral infections in Spain (2002)Estimated risk of transfusion…Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases (2000)Nucleic acid amplification te…Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases (2000)Nucleic acid amplification te…Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations (2006)Nucleic acid amplification te…Transfusion risks of yesterday and of today (2003)Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia (2004)Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003) (2005)Seroprevalence of transfusion-transmitted infections among blood donors in Makkah, Saudi Arabia (2024)The Risk of Transfusion-Transmitted Viral Infections (1996)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)NAT of the United States and Canadian blood supply (2000)Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States (1995)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Effect of a National Disaster on Blood Supply and Safety (2003)Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. (2003)10.1016/s0000-0000(03)47688-2 (2000)Risque résiduel de transmission du VIH, du VHC et du VHB par transfusion sanguine entre 1992 et 2002 en France et impact du dépistage génomique viral (2004)Residual risk of transfusion‐transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy (2005)The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations (2005)Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010 (2012)Safety of the Blood Supply in the United States: Opportunities and Controversies (1997)Blood Donor Selection and Screening: Strategies to Reduce Recipient Risk (2002)Comparison of deferral rates using a computerized versus written blood donor questionnaire: a randomized, cross-over study [ISRCTN84429599] (2002)Evaluation of serological transfusion-transmitted viral diseases and mutliplex nucleic acid testing in malaysian blood donors (2013)HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation (2003)Residual infectious disease risk in screened blood transfusion from a high‐prevalence population: Santa Catarina, Brazil (2007)Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil (2017)Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing (2005)Assessing the impact of HBV NAT on window period reduction and residual risk (2006)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)
this work references cited by second hop

References

  • 2000Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases218 cited
  • 2002International application of the Incidence Rate/Window Period model150 cited
  • 2002Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT117 cited
  • 2002Trends in residual risk of transfusion‐transmitted viral infections in France between 1992 and 200098 cited
  • 2002Estimated risk of transfusion‐transmitted viral infections in Spain69 cited
  • 2002Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy45 cited
  • 2000Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases41 cited

Cited by

  • 2006Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations14 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work